Kyverna Therapeutics, Inc.

Healthcare

NASDAQ:KYTX · NASDAQ Global Select

Market Cap $353.40M Beta 1.96 P/E (TTM) -3.1

$8.07 -1.44%

-$0.12 today

52W Low $2.52High $13.67

Vol 1.11M · Avg 0.94M

EPS (TTM) -$2.59Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+150.62%

Period High

$11.25

Period Low

$2.55

Latest

$8.07

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Capricor Therapeutics, Inc.

NASDAQ:CAPR

$1.29B

Allogene Therapeutics, Inc.

NASDAQ:ALLO

$484.08M

Cabaletta Bio, Inc.

NASDAQ:CABA

$468.78M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

$438.73M

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

$386.33M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$343.72M

Silence Therapeutics plc

NASDAQ:SLN

$324.02M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

$294.28M

Editas Medicine, Inc.

NASDAQ:EDIT

$253.51M

Mereo BioPharma Group plc

NASDAQ:MREO

$50.71M

What is the latest KYTX filing?

The latest filing shown is 8-K dated Jun 2, 2026.

How many recent filings does KYTX have?

Intrinsic Alpha currently shows 20 recent filings for KYTX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.